Develops treatments for cardiovascular diseases, focusing on improving patient outcomes through innovative therapies.
CervoMed Inc. is a biotechnology firm specializing in the development and deployment of therapies aimed at addressing age-related neurologic disorders. Central to its mission is the advancement of innovative treatments that target conditions affecting the nervous system.
At the forefront of CervoMed's pipeline is neflamapimod, a promising orally administered small molecule designed to penetrate the brain. This lead drug candidate is being developed for a range of neurodegenerative diseases including dementia with Lewy bodies (DLB), Alzheimer's disease, frontotemporal dementia, and for aiding in the recovery from ischemic stroke.
In addition to neflamapimod, CervoMed is actively pursuing the development of EIP200, a therapeutic candidate designed for central nervous system disorders, currently undergoing preclinical trials. Founded in 2010 and headquartered in Boston, Massachusetts, CervoMed Inc. continues to push the boundaries of neurology-focused biotechnology, aiming to make meaningful advancements in the treatment and management of debilitating neurologic conditions.